Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Propylthiouracil
Drug ID BADD_D01869
Description A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534)
Indications and Usage Used to manage hyperthyroidism which is due to an overactive thyroid gland (Grave's disease).
Marketing Status approved; investigational
ATC Code H03BA02
DrugBank ID DB00550
KEGG ID D00562
MeSH ID D011441
PubChem ID 657298
TTD Drug ID D00MIN
NDC Product Code 33342-314; 67253-651; 68084-964; 49452-6112; 20012-0001; 0228-2348; 70752-171; 59348-0013; 65319-1059
UNII 721M9407IY
Synonyms Propylthiouracil | 6-Propyl-2-Thiouracil | 6 Propyl 2 Thiouracil
Chemical Information
Molecular Formula C7H10N2OS
CAS Registry Number 51-52-5
SMILES CCCC1=CC(=O)NC(=S)N1
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abortion spontaneous18.01.04.0010.014106%Not Available
Acute febrile neutrophilic dermatosis23.03.03.033; 01.02.01.0060.018808%Not Available
Acute hepatic failure09.01.03.0010.032914%Not Available
Acute respiratory distress syndrome10.02.01.067; 22.01.03.001; 24.03.02.0340.009404%
Ageusia17.02.07.001; 07.14.03.003--Not Available
Agranulocytosis01.02.03.0010.047020%Not Available
Alopecia23.02.02.001--
Anaemia01.03.02.0010.014106%
Anxiety19.06.02.0020.014106%
Aplastic anaemia01.03.03.002--Not Available
Arteritis24.12.02.001--Not Available
Arthralgia15.01.02.0010.025391%
Asthenia08.01.01.001--Not Available
Body temperature increased13.15.01.001--Not Available
Chills08.01.09.001; 15.05.03.0160.009404%
Chromaturia20.02.01.002--
Condition aggravated08.01.03.0040.009404%Not Available
Cough22.02.03.0010.014106%
Cutaneous vasculitis23.06.02.001; 24.12.04.008; 10.02.02.0030.018808%Not Available
Deafness neurosensory17.04.07.001; 04.02.01.0020.009404%Not Available
Dermatitis23.03.04.0020.009404%Not Available
Dermatitis exfoliative23.03.07.001; 10.01.01.004--
Disseminated intravascular coagulation24.01.01.010; 01.01.02.0020.014106%
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.001--
Dyspnoea exertional02.11.05.005; 22.02.01.0050.009404%Not Available
Erythema nodosum23.07.02.001; 10.02.01.020--Not Available
Exophthalmos06.09.04.001; 05.02.02.002--Not Available
Eye irritation06.04.05.003--Not Available
Facial paralysis17.04.03.0080.009404%Not Available
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene